FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Factor Viii topics
Factor Viii
Nucleotide
Antibodies
Polynucleotide
Polypeptide
Sialic Acid
Circulatory
Recombinant
Ethylene Glycol
Coagulation
Hemophilia
Physiologic
Endogenous
Prophylaxis
Blood Coagulation

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Factor Viii patents



      
           
This page is updated frequently with new Factor Viii-related patent applications. Subscribe to the Factor Viii RSS feed to automatically get the update: related Factor RSS feeds. RSS updates for this page: Factor Viii RSS RSS


Date/App# patent app List of recent Factor Viii-related patents
08/21/14
20140232029
 Kit for measuring the thrombin generation in a sample of a patient's blood or plasma patent thumbnailKit for measuring the thrombin generation in a sample of a patient's blood or plasma
The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor/phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and cacl2.
08/07/14
20140221611
 Binding molecules for human factor viii and factor viii-like proteins patent thumbnailBinding molecules for human factor viii and factor viii-like proteins
It is an object of the present invention to provide novel binding molecules for factor viii and factor viii-like proteins. Preferred binding molecules of the present invention exhibit not only distinct characteristics for binding of the target factor viii polypeptides but also specific and desirable characteristics for release (elution) of the target polypeptides.
07/10/14
20140193880
 Modified factor viii and factor ix genes and vectors for gene therapy patent thumbnailModified factor viii and factor ix genes and vectors for gene therapy
The present invention relates to a modified and optimized factor viii or factor ix nucleic acid for inclusion in a chimeric virus vector. Use of such vector can be used for treatment of hemophilia..
07/10/14
20140193441
 Method of administering porcine b-domainless fviii patent thumbnailMethod of administering porcine b-domainless fviii
The present invention provides a method of administering porcine b-domainless factor viii (obi-1) to a patient having factor viii deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant b-domainless porcine fviii, termed obi-1, has greater bioavailability compared to the natural porcine fviii partially purified from porcine plasma, termed hyate:c.
06/05/14
20140154233
 Method of purifying therapeutic proteins patent thumbnailMethod of purifying therapeutic proteins
The present invention relates generally to a method of reducing the level of plasminogen and/or tissue plasminogen activator and/or other protease(s) in a solution comprising fibrinogen and/or factor viii and/or von willebrand factor (vwf), the method comprising: (i) passing a feedstock comprising fibrinogen and/or factor viii and/or vwf through a hydrophobic charge-induction chromatographic resin under conditions selected such that the plasminogen and/or tissue plasminogen activator and/or other protease(s) is bound to the resin; and (ii) recovering the solution comprising fibrinogen and/or factor viii and/or vwf which passes through the resin; wherein the concentration of the plasminogen and/or tissue plasminogen activator and/or protease(s) in the recovered solution is reduced by at least 50% compared to the feedstock. Also provided are solutions and pharmaceutical formulations comprising the fibrinogen and/or factor viii and/or vwf recovered by such methods, and uses thereof..
05/22/14
20140140987
 Manufacturing and purification processes of complex protein found in fraction iv to make a separated apo, transferrin, and alpha 1 anti strepsin (a1at) or a combined transferrin/apo/human albumin/a1at and all new found proteins patent thumbnailManufacturing and purification processes of complex protein found in fraction iv to make a separated apo, transferrin, and alpha 1 anti strepsin (a1at) or a combined transferrin/apo/human albumin/a1at and all new found proteins
A method of introducing healthy good human cells to eat up bad damaged cells, comprising administering an effective amount of a healthy good protein containing transferrin, alpha 1-antitrypsin, apolipoprotein a and human albumin. The method further comprises administering an effective amount of a protein containing apoa1/2/4, or administering an effective amount of a protein containing factor ii, factor vii, factor ix and factor x in prothrombin complex concentrate.
05/08/14
20140128325
Von willebrand factor or factor viii and von willebrand factor for the treatment of coagulopathy induced by inhibitors of thrombocytes
The present invention relates to a von willebrand factor for use in the treatment and/or prevention of a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes. Furthermore, the present invention relates to a method of treating and/or preventing a disorder related to a bleeding event associated with a thrombopathy induced by substances inhibiting thrombocytes comprising administering a pharmaceutically effective amount of a von-willebrand-factor (vwf) to a patient in need thereof.
05/01/14
20140121163
Mfg-e8 and uses thereof
Methods of treating cerebral ischemia using milk fat globule epidermal growth factor-factor viii (mfg-e8) are disclosed, as are recombinant human mfg-e8 and its uses in pharmaceutical compositions, products and methods for treating inflammation and organ injury after ischemia/reperfusion, sepsis, and lung injury.. .
05/01/14
20140120071
Recombinant factor viii having enhanced stability following mutation at the a1-c2 domain interface
The invention relates to a recombinant factor viii that includes one or more mutations at an interface of a1 and c2 domains of recombinant factor viii. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity.
03/13/14
20140072561
 Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life patent thumbnailFactor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life
The present invention relates to modified nucleic acid sequences coding for coagulation factor viii (fviii) and for von willebrand factor (vwf) as well as complexes thereof and their derivatives, recombinant expression vectors containing such nucleic acid sequences, host cells transformed with such recombinant expression vectors, recombinant polypeptides and derivatives coded for by said nucleic acid sequences which recombinant polypeptides and derivatives do have biological activities together with prolonged in vivo half-life and/or improved in vivo recovery compared to the unmodified wild-type protein. The invention also relates to corresponding fviii sequences that result in improved expression yield.
02/27/14
20140057848
Factor viii variants having a decreased cellular uptake
The present invention relates to modified coagulation factors. In particular, the present invention relates to modified factor viii molecules having decreased cellular uptake..
02/27/14
20140056861
Recombinant factor viii having increased stability
The present invention relates to a recombinant factor viii that includes one or more mutations that result in enhanced stability of both factor viii and factor viiia. Methods of making and using the recombinant factor viii, and pharmaceutical compositions containing the same are also disclosed.
02/20/14
20140051832
Method for the production of recombinant human factor viii
The object of the present invention is to provide methods for the production of recombinant human factor viii, employing specific endoproteases, thus assuring full proteolytic processing of said factor even during its biosynthesis, consequently avoiding additional purification steps. Other objects of the present invention are the recombinant human factor viii as obtained by said methods, pharmaceutical compositions, related uses and therapeutic methods..
02/20/14
20140051123
Method of increasing the productivity of eucaryotic cells in the production of recombinant fviii
A method of increasing productivity, in particularly cell-specific productivity, of recombinant factor viii (rfviii) produced in a eukaryotic cell suspension during culturing of the eucaryotic cell suspension in a culturing medium containing not more than 500 μm cacl2, at least a non-ionic detergent and other nutrient components needed for the cells to grow and produce rfviii, the cell suspension is cultured under conditions inducing a shear stress mechanically to the eucaryotic cell suspension by adding a power density of at least 3 w/m3.. .
02/06/14
20140037632
Multi-specific antigen-binding molecules and uses thereof
Various bispecific antibodies that specifically bind to both blood coagulation factor ix/activated blood coagulation factor ix and blood coagulation factor x and functionally substitute for the cofactor function of blood coagulation factor viii, that is, the function to promote activation of blood coagulation factor x by activated blood coagulation factor ix, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor viii were successfully discovered..
01/23/14
20140024808
Factor viii polymer conjugates
The invention is a proteinaceous construct comprising a factor viii molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of factor viii, and methods of preparing same.. .
01/16/14
20140018297
Compounds suitable for treatment of haemophilia
The present invention relates to von willebrand (vwf) compounds as well as compositions suitable for treatment of blood clotting diseases. The present invention also relates to pharmaceutical compositions, freeze-dried or liquid, comprising (i) a factor viii molecule and (ii) a vwf compound..
12/26/13
20130345403
Aqueous factor viii solution
The present invention relates to methods for stabilizing fviii in aqueous solutions comprising a relatively high concentration of fviii. The invention furthermore relates to such aqueous solutions as well as use thereof..
12/12/13
20130330345
Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
Various bispecific antibodies that specifically bind to both blood coagulation factor ix/activated blood coagulation factor ix and blood coagulation factor x and functionally substitute for the cofactor function of blood coagulation factor viii, that is, the function to promote activation of blood coagulation factor x by activated blood coagulation factor ix, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor viii were successfully discovered..
11/07/13
20130296244
Variant of antihemophilic factor viii having increased specific activity
The present invention is in the field of hemophilia therapy. It relates to a new variant of antihemophilic factor viii having increased specific activity in comparison to known factor viii products..
11/07/13
20130296243
Modified recombinant factor viii and von willebrand factor and methods of use
The present invention provides novel methods of increasing the survival of a coagulation protein by inhibiting the interaction with a clearance receptor. The invention also provides methods of preparing compositions that inhibit coagulation protein clearance receptors.
10/24/13
20130281671
Systems for factor viii processing and methods thereof
The present invention provides methods of reducing nonprocessed factor viii or a chimeric polypeptide comprising factor viii comprising co-transfecting in a host cell a polynucleotide encoding factor viii with a polynucleotide encoding a protein convertase, where the endogenous processing enzymes of the host cell are insufficient to convert all of the factor viii to its processed isoform; expressing a proprotein convertase from a second polynucleotide in the host cell; and reducing the nonprocessed factor viii by processing with said proprotein convertase.. .
10/17/13
20130274445
Factor viii conjugates
This invention relates to factor viii muteins that are covalently bound, at a predefined site that is not an n-terminal amine, to one or more biocompatible polymers such as polyethylene glycol. The mutein conjugates retain fviii procoagulant activity and have improved pharmacokinetic properties..
10/17/13
20130274194
Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
The present invention provides methods of administering factor viii; methods of administering chimeric and hybrid polypeptides comprising factor viii; chimeric and hybrid polypeptides comprising factor viii; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.. .
10/10/13
20130267468
Factor viii glycoforms
The invention concerns glycosylated proteins having human factor viii activity. In a preferred embodiment, the protein is glycosylated with oligosaccharides that include an alpha-(2,6)-linked sialic acid and a bisecting glcnac linked to a core beta-mannose..
10/10/13
20130266576
Therapeutic factor viii antibodies
The present invention relates to therapeutic fviii antibodies. In particular, the present invention relates to fviii antibodies having the ability to prolong the circulatory half life of fviii.
07/25/13
20130190242
Polymer-von willebrand factor-conjugates
The present invention relates to a proteinaceous construct (also designated as polymer-vwf-conjugate) comprising plasmatic and/or recombinant von willebrand factor (vwf), said vwf being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor viii (fviii) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (peg) or polysialic acid (psa).
07/25/13
20130189239
Conjugated factor viii molecules
The present invention relates to b-domain truncated factor viii molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules..
07/18/13
20130184216
Novel albumin-free factor viii formulations
A factor viii composition formulated without albumin, comprising the following formulation excipients in addition to factor viii: 4% to 10% of a bulking agent selected from the group consisting of mannitol, glycine and alanine; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mm to 5 mm calcium salt; 100 mm to 300 mm nacl; and a buffering agent for maintaining a ph of approximately between 6 and 8. Alternatively, the formulation can comprise 2% to 6% hydroxyethyl starch; 1% to 4% of a stabilizing agent selected from the group consisting of sucrose, trehalose, raffinose, and arginine; 1 mm to 5 mm calcium salt; 100 mm to 300 mm nacl; and a buffering agent for maintaining a ph of approximately between 6 and 8.
07/18/13
20130183280
Stabilized factor viii variants
The present invention relates to modified coagulation factors. In particular, the present invention relates to stabilized factor viii molecules conjugated with a half life extending moiety as well as use of such molecules..
06/13/13
20130150302
Conjugated blood coagulation factor viii
The present invention provides a biocompatible polymer conjugated to fviii via one or more cysteine residues, suitably via a linker across a reduced disulphide bond in fviii, and pharmaceutical compositions comprising such conjugated forms of fviii.. .
06/06/13
20130143818
Factor viii glycoforms
The invention concerns glycosylated proteins having human factor viii activity. In a preferred embodiment, the protein is glycosylated with oligosaccharides that include an alpha-(2,6)-linked sialic acid and a bisecting glcnac linked to a core beta-mannose..
05/30/13
20130137638
Conjugated factor viii molecules
The present invention relates to b-domain truncated factor viii molecules with a modified circulatory half life, said molecule being covalently conjugated with a hydrophilic polymer. The invention furthermore relates to methods for obtaining such molecules as well as use of such molecules..
05/30/13
20130136750
Antibodies which bind factor viii
The invention, in general, features a method of treatment and/or prevention of a thrombotic pathological condition, in a mammal, which includes administering to the mammal in need of such treatment a therapeutically effective amount of a composition including an antibody directed against the c1 domain of factor viii, which is a partially inhibitory antibody of factor viii.. .
05/16/13
20130123181
Factor viii t cell epitope variants having reduced immunogenicity
Provided herein are methods and compositions for preventing or reducing an initial immune response to factor viii in patients suffering from hemophilia a, and for reducing the intensity of the immune response in patients having pre-formed inhibitor antibodies against factor viii.. .
05/09/13
20130116182
Factor viii b cell epitope variants having reduced immunogenicity
Provided herein are methods and compositions for preventing or reducing an initial immune response to factor viii in patients suffering from hemophilia a, and for reducing the intensity of the immune response in patients having pre-formed inhibitor antibodies against factor viii.. .


Popular terms: [SEARCH]

Factor Viii topics: Factor Viii, Nucleotide, Antibodies, Polynucleotide, Polypeptide, Sialic Acid, Circulatory, Recombinant, Ethylene Glycol, Coagulation, Hemophilia, Physiologic, Endogenous, Prophylaxis, Blood Coagulation

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Factor Viii for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Factor Viii with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.1989

3381

1 - 1 - 72